Lab-on-a-Chip Device Market Information: Product (Instruments, Reagents & Consumables), Technology (Microarrays, Microfluidics), Application (Point of Care Diagnostics), and End-User (Biotechnology and Pharmaceutical Companies) – Global Forecast Till 2027

Lab-on-a-Chip Device Market Scenario

The Lab-on-a-Chip device market is projected to reach USD 9.15 Billion by 2030 at CAGR of 8.97% during the forecast period 2022-2030. A Lab-on-a-Chip is a device which integrates one or several laboratory processes on a single integrated circuit of size ranging from millimeters to a few squares. The Lab-on-a-Chip device market is majorly driven by increasing application of lab on chip devices in the medical field in the diagnosis of various infectious diseases which eases sample handling and yields efficient results in a snap of time. Similarly, the use of lab-on-a-chip devices for research purposes is gaining traction due to easy portability, automated biochemical assays, and huge sample handling provision. Moreover, rising demand for miniature devices, advancing fabrication technology, research on biosensors and biomarkers, and economic feasibility of lab-on-a-chip devices are expected to spur the market growth. However, initial higher purchasing rate, as well as lack of awareness about the use of lab-on-a-chip devices in middle-income countries, are major restraints to the market growth.

Regional Market Summary

The Americas is the global leader in Lab-on-a-Chip device market owing to increasing advances in molecular biology and genetic engineering techniques as well as increasing prevalence of infectious diseases.  Additionally, factors such as increasing number of genomic and proteomics research labs government initiatives and funding for research, development of advanced medical treatment options, and rising demand for portable devices are likely to enhance the growth of Lab-on-a-Chip device market in the American region. For instance, According to stats presented in the Centers for Disease Control and Prevention report in the year 2017, around 49.9% of the children between the ages of 6 months to 17 years in the US received an influenza vaccine. Due to the alarming rate of chronic as well as infectious diseases, use of lab-on-a-chip devices is accelerated due to its precision in diagnosis and multiple samples handling feature.

Europe is the second largest market and holds a healthy share in the Lab-on-a-Chip device market due to major driving factors such as the flourishing medical device market, favorable government initiatives to promote life-science and clinical research, rising average per capita income of individuals. For instance, the European Commission stated that the R&D spending by the pharmaceuticals and biotechnology sectors grew by 8.7% in 2014. This investment in R&D along with the ongoing legislative reforms is expected to have a positive impact on the Lab-on-a-Chip device market.

The Asia-Pacific is expected to be the fastest growing market owing to the faster adaptation of healthcare technology, increasing patient pool of chronic and infectious diseases, government initiatives of healthcare reform, increasing number of CROs and research projects on environmental issues. Furthermore, key medical device players have set up their regional headquarters and manufacturing plants in Singapore, China, Japan,  and Australia thus, boosting the growth of Lab-on-a-Chip device market.

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market share owing to the development of the healthcare industry and sound economic status of inhabitants. However, this area has the possibility to grow during the forecast period as due to increasing outbreak of new opportunistic pathogen associated diseases like Ebola, Zika Virus, and Hepatitis B which has attracted key players to set up their R&D centers in this region.

Market Segmentation & Key players

Lab-on-a-Chip device Market, by Product

• Instruments


• Reagents & Consumables


• Software


• Others

Lab-on-a-Chip device Market, by Technology

• Microarrays


• Microfluidics


• Tissue biochip


• Others

Lab-on-a-Chip Market, by Application

• Genomics


• Proteomics


• Point of Care Diagnostics


• Drug Discovery


• Other

Lab-on-a-Chip Market, by End-User

• Hospitals and Clinics


• Biotechnology and Pharmaceutical Companies


• Forensic Laboratories


• Diagnostics Centers


• Academic & Research Institutes

Lab-on-a-Chip device market, By Region

North America

• US


• Canada

South America

Europe

• Western Europe


• Germany


• France


• UK


• Italy


• Spain


• Rest of Western Europe


• Eastern Europe

Asia-Pacific

• Japan


• China


• India


• Australia


• Republic of Korea


• Rest of Asia-Pacific

Middle East and Africa

• United Arab Emirates


• Saudi Arabia


• Oman


• Kuwait


• Qatar


• Rest of the Middle East & Africa

Market Players

• Becton, Dickinson and Company


• Agilent Technologies, Inc.


• Danaher Corporation


• Bio-Rad Laboratories


• Abbott Laboratories


• Hoffmann-La Roche AG


• PerkinElmer, Inc.


• IDEX Corporation


• Thermo Fisher Scientific, Inc.


• Cepheid Inc.


• Biacore AB

Intended Audience

• Pharmaceutical Manufacturers and Suppliers


• Medical Research Laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Potential Investors